Journal
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 21, Issue 2, Pages 294-302Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jtha.2022.11.017
Keywords
haemostasis; neoplasms; thrombosis; venous thromboembolism; women
Categories
Ask authors/readers for more resources
This study aimed to assess the incidence of VTE and bleeding within 30 days following major surgery in patients with ovarian cancer and evaluate the association between VTE and thromboprophylaxis duration. The study found that the cumulative incidence of VTE was considerable in patients with ovarian cancer following major surgery, but extended thromboprophylaxis did not significantly lower the risk of VTE. Overall, the importance of this article is 7 out of 10.
Background: Venous thromboembolism (VTE) is a frequent complication in patients with ovarian cancer after major surgery. Based on limited data, international guidelines recommend extended thromboprophylaxis for up to 28 days. Objectives: To assess the incidence of VTE and bleeding within 30 days following major surgery in patients with ovarian cancer and to evaluate the association between VTE and thromboprophylaxis duration. Methods: This was a single-center, retrospective, before-after cohort study in patients with ovarian cancer undergoing major surgery. Before July 2019, the local protocol mandated a standard course of thromboprophylaxis during hospital stay only. From July 2019 onward, patients received extended thromboprophylaxis for 28 days. The cumulative incidences of VTE and major bleeding within 30 days after surgery were estimated using the Kaplan-Meier method, with 95% confidence intervals (CIs). Cox regression analysis was performed to evaluate the association between thromboprophylaxis duration and VTE incidence. Results: Between January 2018 and December 2020, 250 women were included, of which 118 (47.2%) received extended and 132 (52.8%) standard thromboprophylaxis. During follow-up, 12 patients developed VTE (cumulative incidence, 4.8%; 95% CI, 2.1-7.4) and 2 major bleeding (cumulative incidence 0.8%; 95% CI, 0.0-1.9). Compared with standard thromboprophylaxis, VTE incidence was numerically lower with extended duration of thromboprophylaxis (5/118 [4.2%] vs 7/132 [5.3%]) but not significantly different (hazard ratio, 0.80; 95% CI, 0.25-2.52). The risk of major bleeding was similar in both groups (1/118 [0.8%] vs 1/132 [0.8%]; hazard ratio, 1.12; 95% CI, 0.07-17.89). Conclusions: The cumulative VTE incidence in patients with ovarian cancer following major surgery was considerable. Extended thromboprophylaxis was safe and associated with a numerically lower risk of VTE but not significantly different.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available